Beyond Air to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Beyond Air, Inc. (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, has announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference. The event will take place on October 9th at the Metropolitan Club in New York.
Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will be available for one-on-one meetings during the conference. Interested parties are encouraged to contact their ROTH representative to schedule a meeting. This participation provides an opportunity for Beyond Air to engage with potential investors and industry professionals, showcasing their innovative work in nitric oxide-based medical solutions.
Beyond Air, Inc. (NASDAQ: XAIR), una società di dispositivi medici e biopharmaceutica in fase commerciale, focalizzata sull'utilizzo del potere dell'ossido nitrico (NO) per migliorare la vita dei pazienti, ha annunciato la sua partecipazione alla 3ª Conferenza Annuale ROTH sulle Opportunità nel Settore Sanitario. L'evento si svolgerà il 9 ottobre presso il Metropolitan Club di New York.
Steve Lisi, Presidente e Amministratore Delegato di Beyond Air, sarà disponibile per incontri one-to-one durante la conferenza. Le parti interessate sono invitate a contattare il proprio rappresentante ROTH per programmare un incontro. Questa partecipazione offre a Beyond Air l'opportunità di interagire con potenziali investitori e professionisti del settore, mostrando il loro lavoro innovativo nelle soluzioni mediche basate sull'ossido nitrico.
Beyond Air, Inc. (NASDAQ: XAIR), una empresa de dispositivos médicos y biofarmacéutica en etapa comercial, enfocada en aprovechar el poder del óxido nítrico (NO) para mejorar la vida de los pacientes, ha anunciado su participación en la 3ª Conferencia Anual ROTH de Oportunidades en Salud. El evento tendrá lugar el 9 de octubre en el Metropolitan Club de Nueva York.
Steve Lisi, Presidente y Director Ejecutivo de Beyond Air, estará disponible para reuniones individuales durante la conferencia. Se alienta a las partes interesadas a contactar a su representante de ROTH para programar una reunión. Esta participación brinda a Beyond Air la oportunidad de interactuar con posibles inversores y profesionales de la industria, mostrando su trabajo innovador en soluciones médicas basadas en óxido nítrico.
Beyond Air, Inc. (NASDAQ: XAIR)는 환자의 삶을 개선하기 위해 산화질소(NO)의 힘을 활용하는 데 주력하는 상업 단계의 의료 기기 및 생명공학 회사로, 제3회 연례 ROTH 건강 기회 회의에 참여한다고 발표했습니다. 이 행사는 10월 9일 뉴욕의 메트로폴리탄 클럽에서 열립니다.
Beyond Air의 회장이자 CEO인 Steve Lisi는 회의 동안 1:1 회의를 위해 참석할 예정입니다. 관심 있는 분들은 회의 일정을 잡기 위해 ROTH 대표에게 연락하시기 바랍니다. 이번 참여는 Beyond Air가 잠재 투자자 및 산업 전문가와 교류하고, 산화질소 기반 의학 솔루션에서의 혁신적인 작업을 선보일 수 있는 기회를 제공합니다.
Beyond Air, Inc. (NASDAQ: XAIR), une entreprise de dispositifs médicaux et de biopharmaceutiques en phase commerciale, axée sur l'exploitation du pouvoir du monoxyde d'azote (NO) pour améliorer la vie des patients, a annoncé sa participation à la 3ème Conférence Annuelle ROTH sur les Opportunités en Santé. L'événement aura lieu le 9 octobre au Metropolitan Club de New York.
Steve Lisi, Président et Directeur Général de Beyond Air, sera disponible pour des réunions individuelles pendant la conférence. Les parties intéressées sont encouragées à contacter leur représentant ROTH pour planifier une réunion. Cette participation offre à Beyond Air l'opportunité d'interagir avec des investisseurs potentiels et des professionnels du secteur, mettant en avant leur travail innovant sur les solutions médicales à base de monoxyde d'azote.
Beyond Air, Inc. (NASDAQ: XAIR), ein Unternehmen in der kommerziellen Phase für medizinische Geräte und Biopharmazeutika, das sich darauf konzentriert, die Kraft von Stickstoffmonoxid (NO) zu nutzen, um das Leben der Patienten zu verbessern, hat seine Teilnahme an der 3. Jahreskonferenz ROTH zu Gesundheitsmöglichkeiten angekündigt. Die Veranstaltung findet am 9. Oktober im Metropolitan Club in New York statt.
Steve Lisi, Chairman und CEO von Beyond Air, wird während der Konferenz für Einzelgespräche zur Verfügung stehen. Interessierte Parteien werden ermutigt, ihren ROTH-Vertreter zu kontaktieren, um ein Meeting zu vereinbaren. Diese Teilnahme bietet Beyond Air die Gelegenheit, mit potenziellen Investoren und Branchenfachleuten zu interagieren und ihre innovativen Arbeiten im Bereich der auf Stickstoffmonoxid basierenden medizinischen Lösungen zu präsentieren.
- None.
- None.
GARDEN CITY, N.Y., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in one-on-one meetings at the 3rd Annual ROTH Healthcare Opportunities Conference to be held at the Metropolitan Club in New York on October 9th.
If you are interested in requesting a one-on-one meeting at the conference, please contact your ROTH representative.
About LungFit®*
Beyond Air’s LungFit is a cylinder-free, phasic flow generator and delivery system and has been designated as a medical device by the U.S. Food and Drug Administration (FDA). The ventilator compatible version of the device can generate NO from ambient air on demand for delivery to the lungs at concentrations ranging from 1 ppm to 80 ppm. The LungFit system could potentially replace large, high-pressure NO cylinders providing significant advantages in the hospital setting, including greatly reducing inventory and storage requirements, improving overall safety with the elimination of NO2 purging steps, and other benefits. LungFit can also deliver NO at concentrations at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting (e.g. COVID-19, bronchiolitis) and chronic, refractory lung infections in the home setting (e.g. NTM). With the elimination of cylinders, Beyond Air intends to offer NO treatment in the home setting.
* Beyond Air’s LungFit PH is approved for commercial use only in the United States of America to treat term and near-term neonates with hypoxic respiratory failure. Beyond Air’s other LungFit systems are not approved for commercial use and are for investigational use only. Beyond Air is not suggesting NO use over 80 ppm or use at home.
About Nitric Oxide
Nitric Oxide is a powerful molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions. In the airways, NO targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs. Currently, exogenous inhaled NO is used in adult respiratory distress syndrome, post certain cardiac surgeries and persistent pulmonary hypertension of the newborn to treat hypoxemia. Additionally, NO is believed to play a key role in the innate immune system and in vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, including both gram-positive and gram-negative, but also against other diverse pathogens, including mycobacteria, viruses, fungi, yeast and parasites, and has the potential to eliminate multi-drug resistant strains.
About Beyond Air®, Inc.
Beyond Air is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval for its first system, LungFit® PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19), and nontuberculous mycobacteria (NTM) among others. Also, the Company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.
Forward Looking Statements
This press release contains “forward-looking statements” concerning the potential safety and efficacy of inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate, as well as its therapeutic potential in a number of indications; and the potential impact on patients and anticipated benefits associated with inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate. Forward-looking statements include statements about expectations, beliefs, or intentions regarding product offerings, business, results of operations, strategies or prospects. You can identify such forward-looking statements by the words “appears,” “expects,” “plans,” “anticipates,” “believes” “expects,” “intends,” “looks,” “projects,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks related to the ability to raise additional capital; the timing and results of future pre-clinical studies and clinical trials; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for our product candidates; the approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; the ability to fund and the results of further pre-clinical studies and clinical trials of our product candidates; obtaining, maintaining and protecting intellectual property utilized by products; obtaining regulatory approval for products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators; and other risks, which may, in part, be identified and described in the “Risk Factors” section of Beyond Air’s most recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on Beyond Air’s website. Beyond Air and Beyond Cancer undertake no obligation to update, and have no policy of updating or revising, these forward-looking statements, except as required by applicable law.
CONTACTS:
Investor Relations contacts
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Cdavis@lifesciadvisors.com
(212) 915-2577
FAQ
When and where is Beyond Air (XAIR) participating in the ROTH Healthcare Opportunities Conference?
Who will represent Beyond Air (XAIR) at the ROTH Healthcare Conference?
What type of meetings will Beyond Air (XAIR) be conducting at the ROTH conference?
How can investors schedule a meeting with Beyond Air (XAIR) at the ROTH conference?
What is the main focus of Beyond Air (XAIR) as a company?
